Novartis' breakthrough heart failure medicine LCZ696, now called Entresto(TM) receives FDA approval

WASHINGTON - July 8, 2015 - PRLog -- The US Food and Drug Administration (FDA) has officially greenlighted Novartis’ heart failure drug Entresto(TM)  formerly known as LCZ696 to treat heart failure with reduced ejection fraction. Entresto was revealed to be superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done, the PARADIGM-HF.  Results from the study revealed patients with reduced ejection fraction who were given Entresto  were more likely to be alive and less likely to undergo hospitalization for heart failure in comparison to the ACE-inhibitor enalapril.

According to Novartis, fundamental clinical data revealed that Entresto:

***reduced the risk of death from cardiovascular causes by 20% (p=0.00004)

***reduced heart failure hospitalizations by 21% (p=0.00004)

***reduced the risk of all-cause mortality by 16% (p=0.0005)

"The very meaningful survival advantage of Entresto seen in the PARADIGM-HF trial should persuade physicians to consider Entresto for all appropriate patients, in place of traditional ACE inhibitors or angiotensin receptor blockers," said Dr. Milton Packer, Professor and Chair for the Department of Clinical Sciences at University of Texas Southwestern Medical Center, Texas, USA. "Entresto is expected to change the management of patients with HFrEF for years to come."

Heart failure affects approximately 6 million individuals in the Unites States and is one of leading causes of hospitalization. Based on the remarkable clinical results, industry analysts have helmed this treatment as the biggest breakthrough to treat heart failure in more than a decade.

Candidates who want to break into pharmaceutical sales:

Now is the time to enter this wonderful career field! With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained and have the background to promote their product both proficiently and efficiently.

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.